The Top 10 Pharmaceutical & Biotechnology R&D Investors
Add bookmark
Innovation is impossible without proper funding
Research based pharmaceutical companies are always striving to make advancements in science and technology, but this innovation comes at a price, R&D investment. Research and development of new therapies involves a complex, expensive, time-intensive and risky process. According to the Tufts Center for the Study of Drug Development, the cost of developing a new drug is at least $1.3 billion.
The Annual EU Industrial R&D Investment Scoreboard (the Scoreboard) contains economic and financial data for the world's top 2000 companies ranked by their investments in research and development (R&D). According to 2013 scoreboard pharmaceutical and biotechnology companies make up four of the world's top ten R&D investors: We take a closer look below at the Top 10 Pharmaceutical & Biotechnology R&D Investors in the world:
World - 2000 companies ranked by R&D World Rank Name Country R&D 2012 (€million)
R&D 1 year growth
(%)
R&D 3 years growth (CAGR-3y, %) R&D intenstiy (%) #6 Roche Switzerland 7007.8 5.0 -3.8 18.6 #7 Novartis Switerzland 6922.8 0.8 5.7 16.1 #8 Merck US USA 5995.9 0.4 9.0 16.7 #9 Johnson & Johnson USA 5809.5 1.6 1.6 11.4 #10 Pfizer USA 5740.5 -14.0 -2.2 12.8 #15 Sanofi-aventis France 4909.0 2.4 2.4 14.0 #20 GlaxoSmithKline UK 4229.0 -3.5 -2.5 13.4 #26 Eli Lilly USA 4000.4 5.1 5.3 23.4 #33 AstraZeneca UK 3375.0 -5.6 5.2 15.9 #35 Abbott Laboratories USA 3275.9 4.7 16.4 10.8
